Excess mortality with erythropoietins

The MHRA has asked manufacturers of recombinant human erythropoietins (r-HeEPOs) to update their safety advice, following publication of data showing a consistent, unexplained excess mortality in patients with anaemia associated with cancer.

In addition, studies suggest that treatment of anaemia with r-HeEPOs in patients with chronic kidney disease to achieve relatively high target haemoglobin levels may be associated with an increased risk of mortality and cardiovascular morbidity.

The new advice outlines changes to dose recommendations, including, where necessary, to stipulate a uniform target haemoglobin concentration range of 10—12 g/dL. Haemoglobin levels higher than 12g/dL should be avoided

Further information: MHRA

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more